Associated Genetic Biomarkers
Dihydropyrimidine dehydrogenase (DPYD) is a gene that encodes a protein is a pyrimidine catabolic enzyme. Missense mutations, silent mutations, and nonsense mutations are observed in cancers such as skin cancer, colon cancer, and stomach cancer.
DPYD status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains DPYD status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with DPYD status in the inclusion eligibility criteria most commonly target colorectal adenocarcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are DPYD Deficient Expression and DPYD Loss .
Bevacizumab, fluorouracil, irinotecan, and leucovorin are the most frequent therapies in trials with DPYD as an inclusion criteria .
Significance of DPYD in Diseases
Colorectal Adenocarcinoma +
DPYD is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DPYD status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.